4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001669866-26-000005
CEO AND PRESIDENT sold 122,918 shares at an average $81.49 ($10,016,381)
- CEO AND PRESIDENT acquired 122,918 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Garcia Marino CEO AND PRESIDENT | 2026-03-12 | Option exercise 10b5-1 | +122,918 | $6.70 | $823,551 | 122,918 | D: show line 1 in the form |
| Garcia Marino CEO AND PRESIDENT | 2026-03-12 | Sale 10b5-1 | −43,505 | $80.69 | $3,510,418 | 79,413 | D: show line 2 in the form |
| Garcia Marino CEO AND PRESIDENT | 2026-03-12 | Sale 10b5-1 | −65,517 | $81.74 | $5,355,360 | 13,896 | D: show line 3 in the form |
| Garcia Marino CEO AND PRESIDENT | 2026-03-12 | Sale 10b5-1 | −12,796 | $82.60 | $1,056,950 | 1,100 | D: show line 4 in the form |
| Garcia Marino CEO AND PRESIDENT | 2026-03-12 | Sale 10b5-1 | −200 | $83.38 | $16,676 | 900 | D: show line 5 in the form |
| Garcia Marino CEO AND PRESIDENT | 2026-03-12 | Sale 10b5-1 | −900 | $85.53 | $76,977 | 0 | D: show line 6 in the form |
| Open-market sales · 122,918 sh · avg $81.49 · $10,016,381 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Garcia Marino CEO AND PRESIDENT | 2026-03-12 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −122,918 | 59,741 | D: show line 7 in the form |
Loading xslF345X05/ownership.xml…